Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients

• Published in: Molecular cancer therapeutics Vol. 13; no. 7; pp. 1777 - 1790
• Main Authors: Singer, Josef, Fazekas, Judit, Wang, Wei, Weichselbaumer, Marlene, Matz, Miroslawa, Mader, Alexander, Steinfellner, Willibald, Meitz, Sarah, Mechtcheriakova, Diana, Sobanov, Yuri, Willmann, Michael, Stockner, Thomas, Spillner, Edzard, Kunert, Renate, Jensen-Jarolim, Erika
• Format: Journal Article
• Language: English
• Published: United States 01.07.2014
• Subjects: Animals; Cell Growth Processes - immunology; CHO Cells; Circular Dichroism; Cricetinae; Cricetulus; Dog Diseases - immunology; Dog Diseases - therapy; Dogs; ErbB Receptors - immunology; ErbB Receptors - metabolism; Humans; Immunization, Passive - methods; Immunoglobulin G - immunology; Models, Molecular; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - therapy; Neoplasms - veterinary; Transfection
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.mct-13-0288

Passive immunotherapy with monoclonal antibodies represents a cornerstone of human anticancer therapies, but has not been established in veterinary medicine yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between humans and dogs, and considering the effectiveness of the anti-EGFR antibody cetuximab in human clinical oncology, we present here a "caninized" version of this antibody, can225IgG, for comparative oncology studies. Variable region genes of 225, the murine precursor of cetuximab, were fused with canine constant heavy gamma and kappa chain genes, respectively, and transfected into Chinese hamster ovary (CHO) DUKX-B11 cells. Of note, 480 clones were screened and the best clones were selected according to productivity and highest specificity in EGFR-coated ELISA. Upon purification with Protein G, the recombinant cetuximab-like canine IgG was tested for integrity, correct assembly, and functionality. Specific binding to the surface of EGFR-overexpressing cells was assessed by flow cytometry and immunofluorescence; moreover, binding to canine mammary tissue was demonstrated by immunohistochemistry. In cell viability and proliferation assays, incubation with can225IgG led to significant tumor cell growth inhibition. Moreover, this antibody mediated significant tumor cell killing via phagocytosis in vitro. We thus present here, for the first time, the generation of a canine IgG antibody and its hypothetical structure. On the basis of its cetuximab-like binding site, on the one hand, and the expression of a 91% homologous EGFR molecule in canine cancer, on the other hand, this antibody may be a promising research compound to establish passive immunotherapy in dog patients with cancer.